437 Optimised achilles VELOSTM process 2b manufacturing platform generates a significant dose boost of reactive CD8 and CD4 clonal neoantigen-reactive T cells for the treatment of solid cancer

• Sergio A Quezada,
• Katy Newton,
• Monica Sassi,
• Sandro Gomez,
• Evi Rologi,
• Meghan Madigan,
• Joanne Tang,
• Sarah Thirkell,
• Samuel Jide Banwo,
• Temi Ogunleye,
• Sophie McKeeman,
• Claire Law,
• Unnaamalai Meyyappan,
• Eleni Kotsiou,
• Theres Oakes,
• Miha Kosmac,
• Luke Goodsell,
• Connor Carolan,
• Justin Ahern,
• Tim Hillyer,
• Bongi Ndlovu,
• Henrieta Fraser,
• Edward Samuel

Affiliations

Sergio A Quezada

1Achilles Therapeutics UK Ltd, London, UK

Katy Newton

Department of Surgery, Manchester University NHS Foundation Trust, Manchester, Greater Manchester, UK

Monica Sassi

1Achilles Therapeutics UK Ltd, London, UK

Sandro Gomez

1Achilles Therapeutics UK Ltd, London, UK

Evi Rologi

1Achilles Therapeutics UK Ltd, London, UK

Meghan Madigan

1Achilles Therapeutics UK Ltd, London, UK

Joanne Tang

1Achilles Therapeutics UK Ltd, London, UK

Sarah Thirkell

1Achilles Therapeutics UK Ltd, London, UK

Samuel Jide Banwo

1Achilles Therapeutics UK Ltd, London, UK

Temi Ogunleye

1Achilles Therapeutics UK Ltd, London, UK

Sophie McKeeman

1Achilles Therapeutics UK Ltd, London, UK

Claire Law

1Achilles Therapeutics UK Ltd, London, UK

Unnaamalai Meyyappan

1Achilles Therapeutics UK Ltd, London, UK

Eleni Kotsiou

1Achilles Therapeutics UK Ltd, London, UK

Theres Oakes

1Achilles Therapeutics UK Ltd, London, UK

Miha Kosmac

1Achilles Therapeutics UK Ltd, London, UK

Luke Goodsell

1Achilles Therapeutics UK Ltd, London, UK

Connor Carolan

1Achilles Therapeutics UK Ltd, London, UK

Justin Ahern

1Achilles Therapeutics UK Ltd, London, UK

Tim Hillyer

1Achilles Therapeutics UK Ltd, London, UK

Bongi Ndlovu

1Achilles Therapeutics UK Ltd, London, UK

Henrieta Fraser

1Achilles Therapeutics UK Ltd, London, UK

Edward Samuel

1Achilles Therapeutics UK Ltd, London, UK